{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T11:58:22Z","timestamp":1768564702255,"version":"3.49.0"},"reference-count":43,"publisher":"Public Library of Science (PLoS)","issue":"1","license":[{"start":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T00:00:00Z","timestamp":1768435200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007219","name":"Natural Science Foundation of Shanghai Municipality","doi-asserted-by":"publisher","award":["21ZR1407900"],"award-info":[{"award-number":["21ZR1407900"]}],"id":[{"id":"10.13039\/100007219","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS One"],"abstract":"<jats:p>\n                    Human epidermal growth factor receptor 2 (HER2), a ligand-independent tyrosine kinase receptor belonging to the EGFR family, serves as a key oncogenic driver in breast, gastric, and several other solid tumors. Although anti-HER2 therapies have substantially improved survival outcomes\u2014particularly in breast and gastric cancers\u2014treatment resistance and cancer recurrence remain major clinical challenges. Thus, developing novel antibodies exhibiting complementary effects to the current anti-HER2 therapies could provide additional therapeutic benefits. Here, we describe two novel HER2-targeting monoclonal antibodies, m66 (murine-derived) and r40 (rabbit-derived), which inhibit breast cancer cell proliferation\n                    <jats:italic>in vitro<\/jats:italic>\n                    . Of the two, antibody r40 exhibits stronger suppression of the PI3K\/AKT and MAPK signaling pathways compared to m66. Moreover, the addition of r40 to the combination of trastuzumab and pertuzumab leads to a significantly enhanced inhibitory effect. We also determined the cryo-EM structures of the HER2-m66-trastuzumab ternary complex and the HER2-r40-trastuzumab-pertuzumab tetrameric complex, at overall resolutions of 3.2 A\u030a and 3.1 A\u030a, respectively. Structural analyses reveal that m66 recognizes an epitope overlapping with that of pertuzumab, whereas r40 binds within the HER2 ECD III\/IV\u2014a region distinct from the binding sites of both trastuzumab and pertuzumab. These findings identify r40 as a promising therapeutic candidate for use in combination with trastuzumab and pertuzumab in the treatment of HER2-positive breast cancer.\n                  <\/jats:p>","DOI":"10.1371\/journal.pone.0338127","type":"journal-article","created":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T18:23:06Z","timestamp":1768501386000},"page":"e0338127","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":0,"title":["Inhibition of HER2 signaling and breast cancer cell growth with a novel antibody targeting HER2 ECD III\/IV"],"prefix":"10.1371","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4589-6192","authenticated-orcid":true,"given":"Chunchun","family":"Liu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3512-237X","authenticated-orcid":true,"given":"Yulei","family":"Ren","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xuan","family":"Luo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peiyun","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiangjuan","family":"Du","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qianmin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xue","family":"Han","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanhui","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ping","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4055-4214","authenticated-orcid":true,"given":"Dan","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huirong","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2026,1,15]]},"reference":[{"issue":"7","key":"pone.0338127.ref001","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1038\/nrm1962","article-title":"EGF-ERBB signalling: towards the systems level","volume":"7","author":"A Citri","year":"2006","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"1","key":"pone.0338127.ref002","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1038\/s41467-023-37029-3","article-title":"An anti-HER2 biparatopic antibody that induces unique HER2 clustering and complement-dependent cytotoxicity","volume":"14","author":"NE Weisser","year":"2023","journal-title":"Nat Commun"},{"issue":"10","key":"pone.0338127.ref003","doi-asserted-by":"crossref","first-page":"5276","DOI":"10.1128\/MCB.16.10.5276","article-title":"A hierarchical network of interreceptor interactions determines signal transduction by Neu differentiation factor\/neuregulin and epidermal growth factor","volume":"16","author":"E Tzahar","year":"1996","journal-title":"Mol Cell Biol"},{"issue":"5","key":"pone.0338127.ref004","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.ccr.2009.03.020","article-title":"Ligand-independent HER2\/HER3\/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941","volume":"15","author":"TT Junttila","year":"2009","journal-title":"Cancer Cell"},{"issue":"4","key":"pone.0338127.ref005","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1007\/BF01518520","article-title":"Differential responses of human tumor cell lines to anti-p185HER2 monoclonal antibodies","volume":"37","author":"GD Lewis","year":"1993","journal-title":"Cancer Immunol Immunother"},{"issue":"4","key":"pone.0338127.ref006","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1038\/74704","article-title":"Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets","volume":"6","author":"RA Clynes","year":"2000","journal-title":"Nat Med"},{"issue":"2","key":"pone.0338127.ref007","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.canlet.2005.01.041","article-title":"Herceptin: mechanisms of action and resistance","volume":"232","author":"R Nahta","year":"2006","journal-title":"Cancer Lett"},{"issue":"4","key":"pone.0338127.ref008","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/S1535-6108(04)00083-2","article-title":"Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex","volume":"5","author":"MC Franklin","year":"2004","journal-title":"Cancer Cell"},{"issue":"6","key":"pone.0338127.ref009","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1007\/s00262-005-0058-x","article-title":"Humanization of a recombinant monoclonal antibody to produce a therapeutic HER dimerization inhibitor, pertuzumab","volume":"55","author":"CW Adams","year":"2006","journal-title":"Cancer Immunol Immunother"},{"issue":"5","key":"pone.0338127.ref010","article-title":"Cryo-EM Structure of HER2-trastuzumab-pertuzumab complex","volume":"14","author":"Y Hao","year":"2019","journal-title":"PLoS One"},{"issue":"24","key":"pone.0338127.ref011","doi-asserted-by":"crossref","first-page":"9330","DOI":"10.1158\/0008-5472.CAN-08-4597","article-title":"Strongly enhanced antitumor activity of trastuzumab and pertuzumab combination treatment on HER2-positive human xenograft tumor models","volume":"69","author":"W Scheuer","year":"2009","journal-title":"Cancer Res"},{"issue":"7","key":"pone.0338127.ref012","doi-asserted-by":"crossref","first-page":"2343","DOI":"10.1158\/0008-5472.CAN-03-3856","article-title":"The HER-2-targeting antibodies trastuzumab and pertuzumab synergistically inhibit the survival of breast cancer cells","volume":"64","author":"R Nahta","year":"2004","journal-title":"Cancer Res"},{"issue":"2","key":"pone.0338127.ref013","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1056\/NEJMoa1703643","article-title":"Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer","volume":"377","author":"G von Minckwitz","year":"2017","journal-title":"N Engl J Med"},{"key":"pone.0338127.ref014","article-title":"Lapatinib in breast cancer","author":"D Bilancia","year":"2007","journal-title":"Ann Oncol"},{"issue":"14","key":"pone.0338127.ref015","article-title":"Lapatinib plus capecitabine in breast cancer","volume":"356","author":"G Sonpavde","year":"2007","journal-title":"N Engl J Med"},{"issue":"6","key":"pone.0338127.ref016","doi-asserted-by":"crossref","first-page":"671","DOI":"10.2217\/fon.12.66","article-title":"Neratinib (HKI-272) in the treatment of breast cancer","volume":"8","author":"S L\u00f3pez-Tarruella","year":"2012","journal-title":"Future Oncol"},{"issue":"19","key":"pone.0338127.ref017","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1056\/NEJMoa1209124","article-title":"Trastuzumab emtansine for HER2-positive advanced breast cancer","volume":"367","author":"S Verma","year":"2012","journal-title":"N Engl J Med"},{"issue":"8","key":"pone.0338127.ref018","doi-asserted-by":"crossref","first-page":"2208","DOI":"10.1038\/s41591-024-03021-7","article-title":"Trastuzumab deruxtecan versus trastuzumab emtansine in HER2-positive metastatic breast cancer: long-term survival analysis of the DESTINY-Breast03 trial","volume":"30","author":"J Cort\u00e9s","year":"2024","journal-title":"Nat Med"},{"issue":"1","key":"pone.0338127.ref019","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1038\/s41571-019-0268-3","article-title":"HER2-targeted therapies - a role beyond breast cancer","volume":"17","author":"D-Y Oh","year":"2020","journal-title":"Nat Rev Clin Oncol"},{"issue":"7","key":"pone.0338127.ref020","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1038\/s41591-024-02992-x","article-title":"Trastuzumab deruxtecan in HER2-positive advanced gastric cancer: exploratory biomarker analysis of the randomized, phase 2 DESTINY-Gastric01 trial","volume":"30","author":"K Shitara","year":"2024","journal-title":"Nat Med"},{"issue":"5","key":"pone.0338127.ref021","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1177\/1756283X12450246","article-title":"Trastuzumab: a novel standard option for patients with HER-2-positive advanced gastric or gastro-oesophageal junction cancer","volume":"5","author":"AFC Okines","year":"2012","journal-title":"Therap Adv Gastroenterol"},{"issue":"1","key":"pone.0338127.ref022","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1615\/CritRevOncog.v17.i1.20","article-title":"Intrinsic and acquired resistance to HER2-targeted therapies in HER2 gene-amplified breast cancer: mechanisms and clinical implications","volume":"17","author":"BN Rexer","year":"2012","journal-title":"Crit Rev Oncog"},{"key":"pone.0338127.ref023","doi-asserted-by":"crossref","first-page":"102826","DOI":"10.1016\/j.ctrv.2024.102826","article-title":"Targeting HER2 in solid tumors: Unveiling the structure and novel epitopes","volume":"130","author":"X Liu","year":"2024","journal-title":"Cancer Treat Rev"},{"issue":"3","key":"pone.0338127.ref024","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1158\/1535-7163.MCT-14-0697","article-title":"Targeting Three Distinct HER2 Domains with a Recombinant Antibody Mixture Overcomes Trastuzumab Resistance","volume":"14","author":"MW Pedersen","year":"2015","journal-title":"Mol Cancer Ther"},{"issue":"3","key":"pone.0338127.ref025","doi-asserted-by":"crossref","DOI":"10.1038\/oncsis.2016.25","article-title":"A monoclonal antibody targeting ErbB2 domain III inhibits ErbB2 signaling and suppresses the growth of ErbB2-overexpressing breast tumors","volume":"5","author":"Y Meng","year":"2016","journal-title":"Oncogenesis"},{"issue":"7888","key":"pone.0338127.ref026","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1038\/s41586-021-04084-z","article-title":"Structures of the HER2-HER3-NRG1\u03b2 complex reveal a dynamic dimer interface","volume":"600","author":"D Diwanji","year":"2021","journal-title":"Nature"},{"issue":"1","key":"pone.0338127.ref027","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1038\/s41421-023-00523-5","article-title":"Structure and dynamics of the EGFR\/HER2 heterodimer","volume":"9","author":"X Bai","year":"2023","journal-title":"Cell Discov"},{"key":"pone.0338127.ref028","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.92873","article-title":"Structural dynamics of the active HER4 and HER2\/HER4 complexes is finely tuned by different growth factors and glycosylation","volume":"12","author":"R Trenker","year":"2024","journal-title":"Elife"},{"issue":"4","key":"pone.0338127.ref029","doi-asserted-by":"crossref","first-page":"978","DOI":"10.4161\/mabs.28786","article-title":"Insights into HER2 signaling from step-by-step optimization of anti-HER2 antibodies","volume":"6","author":"W Fu","year":"2014","journal-title":"MAbs"},{"key":"pone.0338127.ref030","doi-asserted-by":"crossref","first-page":"11672","DOI":"10.1038\/ncomms11672","article-title":"Intermolecular biparatopic trapping of ErbB2 prevents compensatory activation of PI3K\/AKT via RAS-p110 crosstalk","volume":"7","author":"R Tamaskovic","year":"2016","journal-title":"Nat Commun"},{"issue":"1","key":"pone.0338127.ref031","doi-asserted-by":"crossref","first-page":"3790","DOI":"10.1038\/s41467-021-23948-6","article-title":"Engineering an anti-HER2 biparatopic antibody with a multimodal mechanism of action","volume":"12","author":"F Kast","year":"2021","journal-title":"Nat Commun"},{"issue":"26","key":"pone.0338127.ref032","doi-asserted-by":"crossref","first-page":"22214","DOI":"10.18632\/oncotarget.4257","article-title":"PYK2 integrates growth factor and cytokine receptors signaling and potentiates breast cancer invasion via a positive feedback loop","volume":"6","author":"M Selitrennik","year":"2015","journal-title":"Oncotarget"},{"issue":"15","key":"pone.0338127.ref033","doi-asserted-by":"crossref","first-page":"2651","DOI":"10.1038\/s41388-021-01719-3","article-title":"Stromal NRG1 in luminal breast cancer defines pro-fibrotic and migratory cancer-associated fibroblasts","volume":"40","author":"M Berdiel-Acer","year":"2021","journal-title":"Oncogene"},{"key":"pone.0338127.ref034","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/j.molimm.2017.05.010","article-title":"Targeting EGFR\/HER2 heterodimerization with a novel anti-HER2 domain II\/III antibody","volume":"87","author":"X Yu","year":"2017","journal-title":"Mol Immunol"},{"key":"pone.0338127.ref035","article-title":"Mechanism of action of anti-HER2 monoclonal antibodies","author":"J Baselga","year":"2001","journal-title":"Ann Oncol"},{"issue":"4","key":"pone.0338127.ref036","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1038\/nmeth.4193","article-title":"MotionCor2: anisotropic correction of beam-induced motion for improved cryo-electron microscopy","volume":"14","author":"SQ Zheng","year":"2017","journal-title":"Nat Methods"},{"issue":"1","key":"pone.0338127.ref037","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jsb.2015.11.003","article-title":"Gctf: Real-time CTF determination and correction","volume":"193","author":"K Zhang","year":"2016","journal-title":"J Struct Biol"},{"issue":"3","key":"pone.0338127.ref038","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/j.jsb.2012.09.006","article-title":"RELION: implementation of a Bayesian approach to cryo-EM structure determination","volume":"180","author":"SHW Scheres","year":"2012","journal-title":"J Struct Biol"},{"key":"pone.0338127.ref039","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.18722","article-title":"Accelerated cryo-EM structure determination with parallelisation using GPUs in RELION-2","volume":"5","author":"D Kimanius","year":"2016","journal-title":"Elife"},{"issue":"3","key":"pone.0338127.ref040","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/nmeth.4169","article-title":"cryoSPARC: algorithms for rapid unsupervised cryo-EM structure determination","volume":"14","author":"A Punjani","year":"2017","journal-title":"Nat Methods"},{"issue":"13","key":"pone.0338127.ref041","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1002\/jcc.20084","article-title":"UCSF Chimera--a visualization system for exploratory research and analysis","volume":"25","author":"EF Pettersen","year":"2004","journal-title":"J Comput Chem"},{"issue":"7873","key":"pone.0338127.ref042","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1038\/s41586-021-03828-1","article-title":"Highly accurate protein structure prediction for the human proteome","volume":"596","author":"K Tunyasuvunakool","year":"2021","journal-title":"Nature"},{"key":"pone.0338127.ref043","doi-asserted-by":"crossref","first-page":"2126","DOI":"10.1107\/S0907444904019158","article-title":"Coot: model-building tools for molecular graphics","volume":"60","author":"P Emsley","year":"2004","journal-title":"Acta Crystallogr D Biol Crystallogr"}],"container-title":["PLOS One"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0338127","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T18:23:14Z","timestamp":1768501394000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0338127"}},"subtitle":[],"editor":[{"given":"Irina V.","family":"Lebedeva","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2026,1,15]]},"references-count":43,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,1,15]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0338127","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,15]]}}}